



- (51) **International Patent Classification:**
G16H 50/20 (2018.01) *G01N 33/50* (2006.01)
- (21) **International Application Number:**
PCT/US2022/018311
- (22) **International Filing Date:**
01 March 2022 (01.03.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/155,683 02 March 2021 (02.03.2021) US
63/298,171 10 January 2022 (10.01.2022) US
- (71) **Applicant:** **DEWPOINT THERAPEUTICS, INC.**
[US/US]; 451 D Street, Suite 104, Boston, Massachusetts 02210 (US).
- (72) **Inventors:** **CHEN, William W.**; c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **MANTEIGA, John C.**; c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **YU, Violeta**; c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **KWONG, Ann D.**; c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **DANDLIKER, Peter Jeffrey**; c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **BEUTEL, Bruce Aaron**; c/o Dewpoint Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **ZHANG, Chi**; c/o Dewpoint



Therapeutics, Inc., 451 D Street, Suite 104, Boston, Massachusetts 02210 (US). **ZENG, Lingyao**; Building 0520, R 8.146, 42096 Wuppertal (DE). **STEFFEN, Andreas**; Saarbrücker Strasse 33, 10405 Berlin (DE). **FREITAG, Daniel Franz**; Goedinghofer Weg 11, 40627 Duesseldorf (DE).

(74) **Agent:** **XIAO, Jian** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** METHODS OF IDENTIFYING A CONDENSATE PHENOTYPE AND USES THEREOF

FIG. 1A**FIG. 1B**

(57) **Abstract:** The present application provides, in some aspects, methods of identifying a condensate of interest associated with a disease. Also provided are methods of identifying a marker for identifying a condensate of interest associated with a disease. In other aspects, provided herein are methods of identifying a therapeutic agent useful for treating a disease via the identified condensate of interest.

[Continued on next page]

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*